Krystal Biotech: Pay

Krystal Biotech paid its 3 named executives $19.6M in total in FY2025 (Dec). CEO Krish S. Krishnan was paid $10.4M of that.

Pay$100 in the stock at the end of FY20 → $262
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Krish S. KrishnanChair and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
4 years
Suma M. KrishnanPresident, R&D
FY2025 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
3 years
Kathryn A. RomanoChief Accounting Officer
FY2025 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
3 years

CEO pay against the pay peers

In FY2024 (Dec), the median CEO pay of the 8 peers with pay on file was $11.8M. The CEO of Krystal Biotech was paid $15.6M, 32% above the median.

  1. 1TG Therapeutics
  2. 2Krystal Biotech
  3. 3BridgeBio Pharma
  4. 4Ultragenyx Pharmaceutical
  5. 5Halozyme Therapeutics
  6. 6INSMED
  7. 7Acadia Pharmaceuticals
  8. 8PTC Therapeutics
  9. 9Agios Pharmaceuticals
  10. 10Amicus TherapeuticsNot disclosed
  11. 11Apellis PharmaceuticalsNot disclosed
  12. 12Biocryst PharmaceuticalsNot disclosed
  13. 13Blueprint MedicinesNot disclosed
  14. 14Corcept TherapeuticsNot disclosed
  15. 15Harmony Biosciences HoldingsNot disclosed
  16. 16ImmunityBioNot disclosed
  17. 17Intra-Cellular TherapiesNot disclosed
  18. 18Iovance BiotherapeuticsNot disclosed
  19. 19SpringWorks TherapeuticsNot disclosed
  20. 20VericelNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.